Certara, a provider of software and scientific consulting services from drug discovery through clinical development, and Veristat, a full-service CRO, have formed an alliance to offer combined services to their clients.

The joint service offering includes: Pharmacokinetic (PK) analysis, PK/Pharmacodynamic (PD) modeling, population PK modeling, trial simulation, clinical biostatistics, medical writing, data management, clinical monitoring, safety management and project management. These combined services will help streamline the drug discovery, development and trial planning processes by improving the efficiency of data collection and analysis and enabling clients to procure value-added services through their existing vendor relationship.

“We look forward to offering Certara’s capabilities to our clients,” said Patrick Flanagan, chief business officer of Veristat. “By combining our core services with their insight and experience, Veristat broadens our delivery platform and is able to more immediately respond to our clients’ outsourcing needs.”

“Veristat specializes in several trial services that lie outside our core domain, and together we can offer more to the client than either organization could alone,” said Daniel Weiner, chief technology officer and head of Certara’s scientific consulting services.

Certara focuses on supporting translational approaches to drug development. It was formed by the acquisition and integration of Tripos, Simcyp and Pharsight. Each brand focuses on a key phase within the drug discovery and development process; combined, they offer scientific modeling, analysis and simulation capabilities that can enable the cross-disciplinary approaches necessary for translational science initiatives. .

Veristat is a science-focused CRO whose offerings include biostatistics, statistical programming, medical writing, clinical monitoring and data management for a single study or an entire clinical program, as well as preparation of integrated summary documents and submission-ready CDISC data for regulatory filings.